Antibody Information
General Information of This Antibody
| Antibody ID | ANI0LUGEX |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-CD46 mAb |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Membrane cofactor protein (CD46) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
hCD46-19 [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 52.34% (Day 30) | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
In vivo efficacy of PNU-conjugated ADCs in NSCLC LU253 PDX subcutaneous models in NOD/SCID mice. A single dose of 0.5 mg/kg hCD46-19 ADC.
|
||||
| In Vivo Model | Non-small cell lung cancer PDX model (PDX: LU253 PDX) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 77.34% (Day 30) | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
In vivo efficacy of PNU-conjugated ADCs in colorectal CR188 PDX subcutaneous models in NOD/SCID mice. A single dose of 0.5 mg/kg hCD46-19 ADC.
|
||||
| In Vivo Model | Colorectal cancer PDX model (PDX: CR188 PDX) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 86.67% (Day 30) | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
In vivo efficacy of PNU-conjugated ADCs in colorectal CR188 PDX subcutaneous models in NOD/SCID mice. A single dose of 1.0 mg/kg hCD46-19 ADC.
|
||||
| In Vivo Model | Colorectal cancer PDX model (PDX: CR188 PDX) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.48% (Day 30) | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
In vivo efficacy of PNU-conjugated ADCs in NSCLC LU253 PDX subcutaneous models in NOD/SCID mice. A single dose of 1.0 mg/kg hCD46-19 ADC.
|
||||
| In Vivo Model | Non-small cell lung cancer PDX model (PDX: LU253 PDX) | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
47.00 pM
|
Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
|
||||
| In Vitro Model | Normal | HEK293T cells | CVCL_0063 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 3.00 nM | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
|
||||
| In Vitro Model | Uterine sarcoma | MES-SA cells | CVCL_1404 | ||
hCD46-29 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
41.00 pM
|
Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
|
||||
| In Vitro Model | Uterine sarcoma | MES-SA cells | CVCL_1404 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.60 nM
|
Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
|
||||
| In Vitro Model | Normal | HEK293T cells | CVCL_0063 | ||
hCD46-25 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
95.00 pM
|
Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
|
||||
| In Vitro Model | Uterine sarcoma | MES-SA cells | CVCL_1404 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
5.19 nM
|
Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
|
||||
| In Vitro Model | Normal | HEK293T cells | CVCL_0063 | ||
hCD46-26 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.10 nM
|
Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
|
||||
| In Vitro Model | Uterine sarcoma | MES-SA cells | CVCL_1404 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.19 nM
|
Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
|
||||
| In Vitro Model | Normal | HEK293T cells | CVCL_0063 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.